Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)

Media Aljanae Reynolds Wheelhouse Life Science Advisors areynolds@wheelhouselsa.com Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Nurix intends to advance NX-5948 into pivotal trial(s) in 2025 "The current results from this study of advanced patients are very impressive for this early stage of development and we are optimistic that NX-5948 has the potential to be an exciting breakthrough for patients with relapse ...